ANAVEX LIFE SCIENCES CORP. (AVXL) Form 10-Q — Aug 28, 2026
Anavex Life Sciences (AVXL) filed its delinquent fiscal Q3 2026 10-Q showing quarterly net income of $7.8 million ($0.08 per share) versus a $13.2 million loss a year ago, driven by a $15.5 million non-cash stock-compensation reversal tied to the for-cause termination of former CEO Christopher Missling. Nine-month net loss narrowed to $3.2 million from $36.6 million in the prior-year period. The company held $118.3 million in cash at June 30, 2026 and expects that balance to fund operations into mid-to-late fiscal 2028.
Key figures
- Eps
- $0.08 Q3 FY26; -$0.03 nine months FY26
- Net Income
- Q3 FY26 net income $7.8M (vs. $13.2M loss year-ago); nine-month net loss $3.2M (vs. $36.6M loss year-ago)
- Cash Position
- 118300000
- Shares Outstanding
- 92696842
- Cash Runway
- mid to late fiscal 2028
- Atm Capacity
- $150 million (2025 Sales Agreement with TD Securities)
- Working Capital
- $112.4 million at June 30, 2026
- Atm Net Proceeds9 M
- $36.4 million (6,026,237 shares issued)
- Total Liabilities
- $7.7 million
- Atm Unused Capacity
- $103.2 million (sales suspended)
- Options Forfeited9 M
- 6019249
- Operating Cash Burn9 M
- $20.7 million
- Stock Comp Reversal Q3
- $17.1 million recovery
- Ceo Termination Comp Reversal
- $15.5 million
Price after filing
Close on the filing date to close N calendar days later (from $2.99). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.